{"title":"Vectura Ventures收购Activaero进入雾化器市场","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I3.2016","DOIUrl":null,"url":null,"abstract":"Furthering it ambition of becoming a speciality pharmaceutical company focused on respiratory diseases, UK-based pulmonary drug delivery company Vectura is to acquire Activaero in a deal worth up to €136 M (US$189 M). With the acquisition, Vectura will extend its technology offering with Activaero’s smart nebuliser-based technology Favorite® (flow and volume regulated inhalation technology). The deal will also strengthen and broaden the therapeutic focus of Vectura’s product pipeline. Activaero’s lead asset is Favolir® (nebulised budesonide by Akita® Jet), an aerosol therapy for patients with severe asthma who are dependent upon oral corticosteroids.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"76 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vectura Ventures into Nebuliser Market with Activaero Purchase\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2014I3.2016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Furthering it ambition of becoming a speciality pharmaceutical company focused on respiratory diseases, UK-based pulmonary drug delivery company Vectura is to acquire Activaero in a deal worth up to €136 M (US$189 M). With the acquisition, Vectura will extend its technology offering with Activaero’s smart nebuliser-based technology Favorite® (flow and volume regulated inhalation technology). The deal will also strengthen and broaden the therapeutic focus of Vectura’s product pipeline. Activaero’s lead asset is Favolir® (nebulised budesonide by Akita® Jet), an aerosol therapy for patients with severe asthma who are dependent upon oral corticosteroids.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"76 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2014I3.2016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2014I3.2016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Vectura Ventures into Nebuliser Market with Activaero Purchase
Furthering it ambition of becoming a speciality pharmaceutical company focused on respiratory diseases, UK-based pulmonary drug delivery company Vectura is to acquire Activaero in a deal worth up to €136 M (US$189 M). With the acquisition, Vectura will extend its technology offering with Activaero’s smart nebuliser-based technology Favorite® (flow and volume regulated inhalation technology). The deal will also strengthen and broaden the therapeutic focus of Vectura’s product pipeline. Activaero’s lead asset is Favolir® (nebulised budesonide by Akita® Jet), an aerosol therapy for patients with severe asthma who are dependent upon oral corticosteroids.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
